Legacy Healthcare SA

Vyjuvek (beremagene geperpavec), Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), could be approved for use across the EU soon, after

Beremagene geperpavec, Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), is among the products that European Medicines Agency might thi

The European Medicines Agency hit a 15-year high for positive drug recommendations in 2024, with 114 new medicines gaining a positive opinion for regulatory approval across the EU from its human medic

The European Medicines Agency is set to decide this week on whether to recommend EU marketing approval for a number of new products, including three orphan medicines. A decision is expected on Bridge